A Bauschke1, A Altendorf-Hofmann2, H Kissler2, A Koch2, C Malessa2, U Settmacher2. 1. Department of General, Visceral and Vascular Surgery, University Hospital Jena, Erlanger Allee 104, 07743, Jena, Germany. astrid.bauschke@med.uni-jena.de. 2. Department of General, Visceral and Vascular Surgery, University Hospital Jena, Erlanger Allee 104, 07743, Jena, Germany.
Abstract
INTRODUCTION: Tumor recurrence is the most frequent cause of death after liver transplantation for hepatocellular carcinoma. We selected ten other prognostic classifications to evaluate their potential to predict the risk of recurrence after LT for HCC as compared to the Milan classification. All of the other scores have not been compared with one another in a single cohort. METHODS: Data of 147 consecutive patients transplanted at our department between 1996 and 2014 were analyzed and staged for morphological and functional scores of underlying liver disease. For long-term follow-up, we analyzed intrahepatic (within the liver ± distant metastases) and extrahepatic (distant metastases only) recurrence separately. RESULTS AND CONCLUSIONS: The median survival time for all patients was 106 months. The 5- and 10-year observed survival rates were 61 and 43%, respectively. The observed cumulative 5- and 10-year recurrence rates were 37 and 39%, respectively, 10-year intrahepatic and extrahepatic recurrence rates were 12 and 27%, respectively. Median survival time after diagnosis of first recurrence was 7.5 (0-120) months; 2 and 18 months for all, intra- and extrahepatic recurrence, respectively. UCSF-, up to seven-, Shanghai Fudan- or Duvoux classifications can identify patients with a cumulative 10-year recurrence rate below 20%. The pre-therapeutic AFP level should be considered in addition to the geometry of the intrahepatic lesions.
INTRODUCTION: Tumor recurrence is the most frequent cause of death after liver transplantation for hepatocellular carcinoma. We selected ten other prognostic classifications to evaluate their potential to predict the risk of recurrence after LT for HCC as compared to the Milan classification. All of the other scores have not been compared with one another in a single cohort. METHODS: Data of 147 consecutive patients transplanted at our department between 1996 and 2014 were analyzed and staged for morphological and functional scores of underlying liver disease. For long-term follow-up, we analyzed intrahepatic (within the liver ± distant metastases) and extrahepatic (distant metastases only) recurrence separately. RESULTS AND CONCLUSIONS: The median survival time for all patients was 106 months. The 5- and 10-year observed survival rates were 61 and 43%, respectively. The observed cumulative 5- and 10-year recurrence rates were 37 and 39%, respectively, 10-year intrahepatic and extrahepatic recurrence rates were 12 and 27%, respectively. Median survival time after diagnosis of first recurrence was 7.5 (0-120) months; 2 and 18 months for all, intra- and extrahepatic recurrence, respectively. UCSF-, up to seven-, Shanghai Fudan- or Duvoux classifications can identify patients with a cumulative 10-year recurrence rate below 20%. The pre-therapeutic AFP level should be considered in addition to the geometry of the intrahepatic lesions.
Authors: Andreas Andreou; Safak Gül; Andreas Pascher; Wenzel Schöning; Hussein Al-Abadi; Marcus Bahra; Fritz Klein; Timm Denecke; Benjamin Strücker; Gero Puhl; Johann Pratschke; Daniel Seehofer Journal: HPB (Oxford) Date: 2014-09-28 Impact factor: 3.647
Authors: Daniel Seehofer; Maxim Nebrig; Timm Denecke; Thomas Kroencke; Wilko Weichert; Martin Stockmann; Rajan Somasundaram; Eckart Schott; Gero Puhl; Peter Neuhaus Journal: Clin Transplant Date: 2012-03-20 Impact factor: 2.863
Authors: Gerd Otto; Sascha Herber; Michael Heise; Ansgar W Lohse; Christian Mönch; Fernando Bittinger; Maria Hoppe-Lotichius; Marcus Schuchmann; Anja Victor; Michael Pitton Journal: Liver Transpl Date: 2006-08 Impact factor: 5.799
Authors: F Y Yao; L Ferrell; N M Bass; J J Watson; P Bacchetti; A Venook; N L Ascher; J P Roberts Journal: Hepatology Date: 2001-06 Impact factor: 17.425
Authors: G Sapisochin; N Goldaracena; S Astete; J M Laurence; D Davidson; E Rafael; L Castells; C Sandroussi; I Bilbao; C Dopazo; D R Grant; J L Lázaro; M Caralt; A Ghanekar; I D McGilvray; L Lilly; M S Cattral; M Selzner; R Charco; P D Greig Journal: Ann Surg Oncol Date: 2014-12-04 Impact factor: 5.344